NHS England has introduced new guide prices for ADHD and autism diagnostic assessments as part of the 2026/27 NHS Payment Scheme, marking the first attempt to standardise funding for these rapidly expanding services.
Under the new framework, adult ADHD assessments are priced at around £700 for virtual consultations and £850 for face-to-face appointments, while autism assessments range from approximately £1,150 to £1,350 depending on age and complexity. The reforms are intended to address what NHS England describes as “unacceptable variation” in pricing, with some providers previously charging up to £2,000 per assessment.
Officials argue that introducing benchmark tariffs will improve consistency, support commissioners and ensure better value for money as demand for neurodevelopmental assessments continues to surge. The move forms part of a broader effort to bring greater structure to ADHD and autism services, which have historically lacked national service specifications and consistent payment models.
Independent providers warn of ‘race to the bottom’
However, independent sector providers have raised strong concerns about the impact of the new pricing model, warning it could significantly reduce the quality of assessments delivered. Industry representatives argue that the lower tariffs may force providers to cut back on the time, staffing and multidisciplinary input required for comprehensive evaluations. Some have described the shift as moving from a “gold standard” approach, involving detailed, multi-session assessments, to a more limited “bronze standard” model.
Clinicians note that high-quality ADHD and autism assessments typically involve multiple stages, including clinical interviews, collateral information gathering, behavioural observations and post-diagnostic support. Reducing funding, they argue, risks compressing these processes into shorter, less thorough consultations. The Independent Healthcare Providers Network has previously highlighted that many providers adhere to rigorous frameworks such as UKAAN and CAAQAS standards, which are considered benchmarks for safe and effective diagnosis. There are concerns that these standards may become harder to maintain if financial constraints limit the resources available per patient.
Rising demand and system pressures driving reform
The tariff changes come against a backdrop of unprecedented demand for ADHD and autism assessments. Referral rates have risen sharply in recent years, with NHS services struggling to keep pace. In many areas, waiting times for autism assessments exceed a year, while ADHD assessments can take several years to access through standard NHS pathways. This surge in demand has led to increased reliance on independent providers through the NHS “Right to Choose” scheme, with large volumes of assessments outsourced to the private sector.
Spending has escalated rapidly as a result. Estimates suggest the NHS has spent hundreds of millions of pounds on private ADHD and autism assessments in recent years, contributing to significant budget pressures. At the same time, concerns about variation in quality and regulation have prompted calls for greater oversight. Previous reviews have highlighted inconsistencies in how assessments are conducted, with no single national standard enforced across all providers. The new pricing framework is therefore seen by policymakers as part of a wider effort to bring greater control and consistency to a fragmented market.
Balancing cost control with clinical quality
The introduction of standardised tariffs raises a fundamental challenge for the NHS: how to balance cost control with the delivery of high-quality, patient-centred care. Supporters of the reforms argue that benchmark pricing will prevent excessive charging and create a more equitable system, ensuring that public funds are used efficiently. They also point out that clearer pricing structures could help commissioners plan services more effectively and reduce unwarranted variation.
However, critics warn that focusing too heavily on cost risks undermining clinical outcomes. If providers are forced to operate within tighter financial constraints, there is a danger that assessments become more transactional and less comprehensive. This could have long-term consequences for patients. Inaccurate or incomplete diagnoses may lead to inappropriate treatment, delayed support or additional demand on NHS services further down the line.
Implications for digital health and service delivery
The debate also has implications for the growing role of digital health in neuro-developmental services. Many ADHD assessments are now delivered online, which can reduce costs and improve access, but may also raise questions about depth and accuracy if not carefully managed. NHS England’s guidance emphasises the need for robust, end-to-end care pathways, including pre-diagnostic support and post-diagnostic follow-up. Digital tools and remote consultations are likely to play an increasing role in meeting demand, but experts stress that technology must complement, rather than replace thorough clinical assessment.
A pivotal moment for neurodevelopmental services
The introduction of new tariffs marks a significant turning point for ADHD and autism services in England. While the reforms aim to bring much-needed structure and financial sustainability to a rapidly expanding sector, they have also exposed tensions between cost efficiency and clinical quality. As implementation begins, the key question will be whether the NHS can maintain high standards of care while operating within tighter financial parameters. For patients awaiting diagnosis, the outcome of this balance will be critical, shaping both the accessibility and the quality of support available in the years ahead.
